Stay informed with the latest litigation news. Explore now

IP Verse

Biogen Idec Ma competitive analysis

Latest publications and patents of Biogen Idec Ma New

Explore the latest publications and patents granted to Biogen Idec Ma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 11, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Biogen Idec Ma

EP2645106
Oct 2, 2024Methods And Products For Evaluating An Immune Response To A Therapeutic AgentPatent Maintained As Amended
EP2701778
Oct 18, 2023A Limiter For A Dispensing DevicePatent Maintained As Amended
EP2653873
Aug 24, 2022Compositions And Uses For Treating Multiple SclerosisGranted And Under Opposition
EP2870250
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses ThereofPatent Maintained As Amended
EP2676967
Aug 14, 2019Methods Of Treating Inflammatory And Autoimmune Diseases With NatalizumabRevoked
EP2715352
Apr 24, 2019Method Of Assessing Risk Of PmlRevoked
EP2483289
Mar 20, 2019Methods Of Preventing And Removing Trisulfide BondsGranted And Under Opposition
EP2707383
Apr 18, 2018Methods Of Preventing And Removing Trisulfide BondsGranted And Under Opposition
EP2877180
Jan 3, 2018Compounds That Are S1P Modulating Agents And/Or Atx Modulating AgentsNo Opposition Filed Within Time Limit
EP1991267
Dec 20, 2017Methods Of Treating Inflammatory And Autoimmune Diseases With NatalizumabRevoked

Latest patents of Biogen Idec Ma opposed by its competitors

Explore Biogen Idec Ma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 18, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2645106
Oct 2, 2024Methods And Products For Evaluating An Immune Response To A Therapeutic Agent1
EP2701778
Oct 18, 2023A Limiter For A Dispensing Device2
EP2653873
Aug 24, 2022Compositions And Uses For Treating Multiple Sclerosis14
EP2870250
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2
EP2676967
Aug 14, 2019Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab1
EP2715352
Apr 24, 2019Method Of Assessing Risk Of Pml1
EP2483289
Mar 20, 2019Methods Of Preventing And Removing Trisulfide Bonds3
EP2707383
Apr 18, 2018Methods Of Preventing And Removing Trisulfide Bonds2
EP1991267
Dec 20, 2017Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab1
EP2524060
Nov 29, 2017Assay For Jc Virus Antibodies1

Latest PTAB cases involving Biogen Idec Ma New

Discover the latest PTAB cases involving Biogen Idec Ma, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 17, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Biogen Idec Ma

IPR2015-01993Sep 28, 2015COALITION FOR AFFORDABLE DRUGS VBIOGEN IDEC MAFinal Written Decision

Top competitors of Biogen Idec Ma

Top competitors of Biogen Idec Ma based on patent oppositions.